UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 32.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 148,132 shares of the company’s stock after buying an additional 36,341 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.07% of Cellebrite DI worth $3,263,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. USS Investment Management Ltd purchased a new stake in Cellebrite DI in the 4th quarter valued at approximately $706,000. Sphera Management Technology Funds Ltd purchased a new position in shares of Cellebrite DI during the 4th quarter worth $881,000. Two Sigma Advisers LP lifted its stake in shares of Cellebrite DI by 35.0% during the 4th quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company’s stock worth $39,899,000 after purchasing an additional 470,000 shares during the period. State of Wyoming lifted its stake in shares of Cellebrite DI by 44.6% during the 4th quarter. State of Wyoming now owns 30,911 shares of the company’s stock worth $681,000 after purchasing an additional 9,530 shares during the period. Finally, Silvercrest Asset Management Group LLC purchased a new position in shares of Cellebrite DI during the 4th quarter worth $4,583,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.
Analyst Upgrades and Downgrades
CLBT has been the topic of a number of recent analyst reports. Needham & Company LLC reduced their price target on Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. JPMorgan Chase & Co. reduced their price target on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, May 12th. Finally, Lake Street Capital increased their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI currently has an average rating of “Buy” and a consensus price target of $22.43.
Cellebrite DI Trading Up 1.1%
Shares of CLBT opened at $16.84 on Friday. The firm has a market capitalization of $4.03 billion, a P/E ratio of -12.12, a price-to-earnings-growth ratio of 4.27 and a beta of 1.32. The stock’s fifty day simple moving average is $18.41 and its 200 day simple moving average is $20.09. Cellebrite DI Ltd. has a twelve month low of $10.42 and a twelve month high of $26.30.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The business’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period last year, the company posted $0.08 EPS. Sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
- Five stocks we like better than Cellebrite DI
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is Meta Plotting a Stablecoin Comeback Years After Libra’s Flop?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Silver’s Options Sizzle: Are Traders Betting on a Breakout?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.